Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05259917 · ClinicalTrials.gov registry record · Phase 3
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
A Phase 3 study, sponsored by KalVista Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT05259917 is a Phase 3 study that has completed, run by KalVista Pharmaceuticals. The registered enrollment target is 136 participants.
The verdict
NCT05259917, a Phase 3 study, has completed, sponsored by KalVista Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients
Interventions
- DRUG Placebo
- DRUG KVD900 600 mg
- DRUG KVD900 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2022-02-22 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05259917
The ClinicalTrials.gov registry entry for NCT05259917 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KalVista Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05259917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05259917 about?
NCT05259917 is a clinical study titled "A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)". This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients
What is the current status of trial NCT05259917?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2022-02-22. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05259917?
The interventions under investigation include: Placebo (DRUG), KVD900 600 mg (DRUG), KVD900 300 mg (DRUG).
Who is sponsoring clinical trial NCT05259917?
This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.